Create Content

Desktop Helper (English)

 

Thumbnail images of the front and back - click image to download.

 

Desktop helper in Spanish (thanks to GRAP and Laboratorios Esteve for their support in organisation of the translation and adaptation)

 

Desktop helper in Portuguese

Summary of Evidence

Thumbnail of images of front and back Summary of Evidence - click image to download.

Authors' declarations of interest

Dr Alan Kaplan has received honoraria for advisory board or speakers bureaux for AstraZeneca, Boehringer Ingelheim, Griffols, GSK, Novartis, Purdue, Pfizer, Teva Trudell and Johnson & Johnson

Dr Miguel Román Rodríguez has received honoraria for educational activities, speaking engagements and advisory boards from AstraZeneca, Boehringer Ingelheim, Chiesi, Gebro, GlaxoSmithKline,  Menarini, Novartis, Pfizer, Rovi and Teva

Professor David Price has board membership with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Meda, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, and Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from Aerocrine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Meda, Mundipharma, Napp, Novartis, Pfizer, Respiratory Effectiveness Group, Takeda, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva; payment for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Meda, Merck, Mundipharma, Novartis, Pfizer, Skyepharma, Takeda, and Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma and Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma and Novartis; payment for travel/accommodation/meeting expenses from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; funding for patient enrolment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals, and Zentiva; stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd, UK and 74% of Observational and Pragmatic Research Institute Pte Ltd, Singapore; and is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, Health Technology Assessment, and Medical Research Council.

Dr Ioanna Tsiligianni has received honoraria for educational activities, speaking engagements and advisory boards from Boehringer Ingelheim, Novartis, AstraZeneca and GlaxoSmithKline.

Disclaimers and licence information

Disclaimer - desktop helpers and opinion sheets

 

 

Return to other desktop helpers